BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Okuse C, Yotsuyanagi H, Nagase Y, Kobayashi Y, Yasuda K, Koike K, Iino S, Suzuki M, Itoh F. Risk factors for retinopathy associated with interferon α-2b and ribavirin combination therapy in patients with chronic hepatitis C. World J Gastroenterol 2006; 12(23): 3756-3759 [PMID: 16773695 DOI: 10.3748/wjg.v12.i23.3756]
URL: https://www.wjgnet.com/1007-9327/full/v12/i23/3756.htm
Number Citing Articles
1
Junaid Siddiqui, Jacinthe Rouleau, Andrew G Lee, Yutaka Sato, Michael D Voigt. Bilateral Optic Neuritis in Acute Hepatitis CJournal of Neuro-Ophthalmology 2009; 29(2): 128 doi: 10.1097/WNO.0b013e3181989783
2
C. Burgueño-Montañés, R. Pérez-Álvarez. Retinopatía asociada a interferón pegilado y ribavirina en pacientes con hepatitis CArchivos de la Sociedad Española de Oftalmología 2011; 86(6): 193 doi: 10.1016/j.oftal.2010.12.015
3
Masaaki Watanabe, Sumie Ogasawara, Akihiko Takahashi, Juichi Takada, Yoshiaki Tanaka, Yusuke Okuwaki, Tsutomu Minamino, Hisashi Hidaka, Takahide Nakazawa, Akitaka Shibuya, Wasaburo Koizumi. Branch retinal artery occlusion and central retinal vein occlusion associated with pegylated interferon plus ribavirin combination therapy for chronic hepatitis CCutaneous and Ocular Toxicology 2012; 31(3): 253 doi: 10.3109/15569527.2011.641197
4
Mohamed Samy Abd Elaziz, Ali Saad Eldeen Nada, Saber Hamid ElSayed, Ghada Salah Nasr, Adel Galal Zaky. Ocular comorbidities with direct-acting antiviral treatment for chronic hepatitis C virus (HCV) patientsInternational Ophthalmology 2020; 40(5): 1245 doi: 10.1007/s10792-020-01290-y
5
Michael R Narkewicz, Philip Rosenthal, Kathleen B Schwarz, Arlene Drack, Todd Margolis, Michael X Repka. Ophthalmologic Complications in Children With Chronic Hepatitis C Treated With Pegylated InterferonJournal of Pediatric Gastroenterology and Nutrition 2010; 51(2): 183 doi: 10.1097/MPG.0b013e3181b99cf0
6
A. Sauer, P. Lenoble, P. Bader, C. Speeg-Schatz, T. Bourcier, X. Nasica. Complications ophtalmologiques du traitement de l’hépatite CJournal Français d'Ophtalmologie 2007; 30(7): 746.e1 doi: 10.1016/S0181-5512(07)91366-2
7
Kayoko Sugawara, Mie Inao, Nobuaki Nakayama, Satoshi Mochida. Telaprevir-induced, but not pegylated interferon-associated, retinopathy as a noteworthy adverse effect during triple antiviral therapy in patients with chronic hepatitis CJournal of Gastroenterology 2014; 49(2): 363 doi: 10.1007/s00535-013-0889-8
8
Yasser M. Fouad, Hanaa Khalaf, Hala Ibraheem, Heba Rady, Amal K. Helmy. Incidence and risk factors of retinopathy in Egyptian patients with chronic hepatitis C virus treated with pegylated interferon plus ribavirinInternational Journal of Infectious Diseases 2012; 16(1): e67 doi: 10.1016/j.ijid.2011.09.022
9
Nasser Mousa, Tarek Besheer, Yahia Gad, Amal Elbendary, Tharwat Mokbel, Azza Abdel-Aziz. Is Combination Therapy Interferon and Ribavirin in Patients with Chronic Hepatitis C Infection Toxic for Eyes?Journal of Ocular Pharmacology and Therapeutics 2013; 29(3): 345 doi: 10.1089/jop.2012.0169
10
Hee Young Kang, Ji Won Lim, Min Chul Shin. Pegylated Interferon Associated Retinopathy in Chronic Hepatitis PatientsJournal of the Korean Ophthalmological Society 2009; 50(3): 383 doi: 10.3341/jkos.2009.50.3.383
11
Chiaki Okuse, Hiroki Ikeda, Yoshihiko Nagase, Norie Yamada, Masaru Okamoto, Minoru Kobayashi, Hideaki Takahashi, Yoshiki Katakura, Kotarou Matsunaga, Nobuyuki Matsumoto, Hiroshi Yotsuyanagi, Kazuhiko Koike, Shiro Iino, Michihiro Suzuki, Fumio Itoh. Frequency and risk factors for retinopathy associated with pegylated interferon α2b and ribavirin combination therapy in patients with chronic hepatitis CKanzo 2008; 49(11): 520 doi: 10.2957/kanzo.49.520
12
Hee Young Kang, Min Chul Shin. Pegylated Interferon-Associated Severe Retinopathy in a Patient with Chronic HepatitisKorean Journal of Ophthalmology 2012; 26(2): 147 doi: 10.3341/kjo.2012.26.2.147
13
A. Viennet, F. Glatre, F. Bacin. Rétinopathie à interferon alpha 2b et ribavirine chez un patient atteint d’une hépatite C chroniqueJournal Français d'Ophtalmologie 2009; 32(7): 505 doi: 10.1016/j.jfo.2009.04.007
14
Shih-Yi Lin, Cheng-Li Lin, Shu-Woei Ju, I-Kuan Wang, Cheng-Chieh Lin, Chih-Hsueh Lin, Wu-Huei Hsu, Ji-An Liang, Tatsuo Kanda. Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort studyPLOS ONE 2017; 12(3): e0173125 doi: 10.1371/journal.pone.0173125
15
C. Burgueño-Montañés, R. Pérez-Álvarez. Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis CArchivos de la Sociedad Española de Oftalmología (English Edition) 2011; 86(6): 193 doi: 10.1016/j.oftale.2010.12.003
16
Supriya Arora, Thamolwan Surakiatchanukul, Tarun Arora, Marie Helene Errera, Hitesh Agrawal, Marco Lupidi, Jay Chhablani. Retinal toxicities of systemic anticancer drugsSurvey of Ophthalmology 2022; 67(1): 97 doi: 10.1016/j.survophthal.2021.05.007
17
A. Raza, S. Mittal, G. K. Sood. Interferon‐associated retinopathy during the treatment of chronic hepatitis C: a systematic reviewJournal of Viral Hepatitis 2013; 20(9): 593 doi: 10.1111/jvh.12135
18
KASL clinical practice guidelines: Management of Hepatitis CClinical and Molecular Hepatology 2014; 20(2): 89 doi: 10.3350/cmh.2014.20.2.89
19
KASL clinical practice guidelines: management of hepatitis CClinical and Molecular Hepatology 2016; 22(1): 76 doi: 10.3350/cmh.2016.22.1.76
20
Reid Longmuir, Andrew G. Lee, Jacinthe Rouleau. Cotton Wool Spots Associated with Interferon Beta-1 Alpha TherapySeminars in Ophthalmology 2007; 22(1): 49 doi: 10.1080/08820530601182725
21
S. Trad, C. Bonnet, D. Monnet. Uvéite médicamenteuse et effets indésirables des médicaments en ophtalmologieLa Revue de Médecine Interne 2018; 39(9): 699 doi: 10.1016/j.revmed.2018.02.017
22
Chien‐Hsiung Lai, Yao‐Hsu Yang, Pau‐Chung Chen, Ying‐Chi King, Chia‐Yen Liu. Retinal vascular complications associated with interferon‐ribavirin therapy for chronic hepatitis C: A population‐based studyPharmacoepidemiology and Drug Safety 2018; 27(2): 191 doi: 10.1002/pds.4363
23
Joon Hyung Yeo, Kyoung Woo Kim, Jae Chan Kim. Mooren’s ulcerative keratitis after systemic pegylated interferon alpha2a in chronic hepatitis CCanadian Journal of Ophthalmology 2017; 52(5): e163 doi: 10.1016/j.jcjo.2017.03.018
24
Shelly Adams, Mark Ostermeier. Retinopathy associated with pegylated interferon and ribavirin treatment for chronic hepatitis COptometry - Journal of the American Optometric Association 2010; 81(11): 580 doi: 10.1016/j.optm.2010.04.094
25
Mark Hull, Stephen Shafran, Alex Wong, Alice Tseng, Pierre Giguère, Lisa Barrett, Shariq Haider, Brian Conway, Marina Klein, Curtis Cooper. CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and TreatmentCanadian Journal of Infectious Diseases and Medical Microbiology 2016; 2016: 1 doi: 10.1155/2016/4385643
26
Zubir S. Rentiya, Matthew Wells, Junun Bae, Kuan-Jen Chen, An-Ning Chao, Nicholas Turgeon, Syed M. Shah, Mostafa Hanout. Interferon-α-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendationsGraefe's Archive for Clinical and Experimental Ophthalmology 2019; 257(3): 447 doi: 10.1007/s00417-018-04209-7
27
J. D. PANETTA, N. GILANI. Interferon‐induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infectionAlimentary Pharmacology & Therapeutics 2009; 30(6): 597 doi: 10.1111/j.1365-2036.2009.04071.x
28
Nicolas Bourgeois, François Chavant, Claire Lafay-Chebassier, Nicolas Leveziel, Marie-Christine Pérault-Pochat. Atteintes rétiniennes iatrogènes : étude cas/non cas dans la banque nationale de pharmacovigilanceTherapies 2016; 71(4): 365 doi: 10.1016/j.therap.2016.02.024
29
G. Ngatcha, F. Rouibaa, S. Majdouli, A. Arouah, A. Feqhi, A. Oubaaz. Rétinopathie à interferon pégylé alpha 2a et ribavirine au cours d’une hépatite virale C chroniqueJournal Africain d'Hépato-Gastroentérologie 2013; 7(1): 53 doi: 10.1007/s12157-012-0444-x
30
Nilesh Mehta, Uma K. Murthy, Vivek Kaul, Samuel Alpert, Gerald Abruzzese, Charles Teitelbaum. Outcome of Retinopathy in Chronic Hepatitis C Patients Treated with Peginterferon and RibavirinDigestive Diseases and Sciences 2010; 55(2): 452 doi: 10.1007/s10620-009-0721-8
31
Menelaos Kanakis, Petros Petrou, Giota Lourida, Ilias Georgalas. Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspectiveSurvey of Ophthalmology 2022; 67(2): 388 doi: 10.1016/j.survophthal.2021.05.013
32
Masako Murata, Yuu Tamura, Masaya Ohsawa, Takao Hirano, Toshihiko Matsuo, Toshinori Murata. Central retinal vein occlusion in hypertensive patients with chronic hepatitis C treated with interferon α and ribavirinJapanese Journal of Ophthalmology 2008; 52(6): 511 doi: 10.1007/s10384-008-0585-z
33
Fatih Selcukbiricik, Deniz Tural, Tuba Elif Senel, Ahmet Sarıca, Ozlem Soyluk, Suheyla Serdengecti. Bilateral Ischemic Optic Neuropathy Developed under Interferon TherapyCase Reports in Ophthalmological Medicine 2012; 2012: 1 doi: 10.1155/2012/102739
34
Shijie Lan, Zhihua Cui, Qiliang Yin, Zhigang Liu, Lingling Liang, Hua He, Hesong Liu, Zhen Guo, Yingying Yu, Di Wu. Prospective study of clinical characteristics of melanoma patients with retinopathy caused by a high-dose interferon α-2bMelanoma Research 2021; 31(6): 550 doi: 10.1097/CMR.0000000000000769
35
Ligita Jancoriene, Dovile Norvydaite, Saulius Galgauskas, Evelina Balciunaite. Transient Visual Loss in a Hepatitis C Patient Treated With Pegylated Interferon Alfa-2a and RibavirinHepatitis Monthly 2014; 14(2) doi: 10.5812/hepatmon.15124
36
Stela Vujosevic, Diego Tempesta, Franco Noventa, Edoardo Midena, Giada Sebastiani. Pegylated interferon-associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifies ophthalmologic screeningHepatology 2012; 56(2): 455 doi: 10.1002/hep.25654
37
Maysa F. Salem, Manal I. El-Bermawy. Effect of interferon, ribavirin, and a combination of both on the retina of adult male albino ratsThe Egyptian Journal of Histology 2015; 38(3): 558 doi: 10.1097/01.EHX.0000470829.83093.5e